Information Provided By: 
Fly News Breaks for June 27, 2019
SURF
Jun 27, 2019 | 12:38 EDT
JonesTrading analyst Soumit Roy started Surface Oncology with a Buy rating and $12 price target. The company's "differentiated approach" involves targeting the first enzyme in the enzymatic pathway, CD39, and a novel target, IL-27, to block overexpression of CD39 and T cell inhibiting receptors, Roy tells investors in a research note. He believes the stock at current levels is "squarely in the oversold territory."
News For SURF From the Last 2 Days
There are no results for your query SURF
